Items tagged with Treatment

Médecins Sans Frontières TB field research in Tajikistan, Uzbekistan and Kyrgyzstan (post)

DOT or SAT for rifampicin-resistant TB? A non-randomized comparison in a high HIV-prevalence setting (post)

Abstract

Addressing TB control in fragile states: Urban DOTS experience in Kabul, Afghanistan, 2009-2015 (post)

Abstract

TB Treatment Trials Grid 2017 (post)

Michael Vjecha, MD compiled for the Tuberculosis Trials Consortium (TBTC) a table containing information about the planned, ongoing, and recently completed randomized TB drug clinical trials.

Bedaquiline effective, safe, manageable across wide range of settings, five-continent data show (post)

Data on patients treated with one of the two newest tuberculosis medicines in 15 countries across five continents show that the treatment, which represents a last resort for hundreds of thousands of people with drug-resistant strains of disease, can be administered safely in a wide range of settings, and bring greatly improved outcomes compared to patients without access to the medicine, according to a recent study.

Outcome of TB treatment and its predictors among HIV-infected patients in southwest Ethiopia (post)

Abstract

Seoul OKs Eugene Bell Foundation's bid to send TB medications, other materials to North Korea (post)

SEOUL, June 27 (Yonhap) -- South Korea's unification ministry has approved the Eugene Bell Foundation Korea's application to send medications for tuberculosis and materials to build hospital wards to North Korea, an official said Tuesday.

Nigeria adopts shorter treatment for drug-resistant TB (post)

Nigeria has adopted a new regimen that reduces the time required for the treatment of multidrug-resistant TB (MDR-TB) from 20 months to about nine months.

Determinants of treatment completion among rural smear positive pulmonary TB patients: a cross-sectional survey conducted in south-western Uganda (post)

Abstract

Denying access to bedaqualine in India costs lives (post)

As physicians managing the so-called Patna patient—an 18-year-old woman who took the Indian government to court after being denied access to bedaqualine—we commend Amber Kunkel and colleagues on their forthright article.¹ The woman's case is emblematic of the desperation of the many patients with advanced drug resistance and with few therapeutic options that we encounter in our clinic. India's National Tuberculosis Program's (RNTCP) insistence on reserving bedaqualine for patients who have at least three susceptible drugs in the background regimen,² denies this drug to the very patients who would most benefit from it, especially since it doubles the chance of a cure.³ It worries us that such patients, denied access to a life-saving drug, are compelled to move the judiciary to access it. The theoretical fear of protecting a drug has sadly taken precedence over protecting lives.